Progress in the field of precision medicine has changed the landscape of cancer therapy.
Precision medicine is propelled by technologies that enable molecular profiling, genomic …

Accumulating evidence shows that cellular and acellular components in tumor
microenvironment (TME) can reprogram tumor initiation, growth, invasion, metastasis, and …

Remarkable progress has been made in the development of new therapies for cancer,
dramatically changing the landscape of treatment approaches for several malignancies and …

Patients with advanced cancer generate 4 million visits annually to emergency departments
(EDs) and other dedicated, high‐acuity oncology urgent care centers. Because of both the …

Germline loss-of-function mutations of the VHL tumor suppressor gene cause von Hippel–
Lindau disease, which is associated with an increased risk of hemangioblastomas, clear cell …

Contemporary anticancer drugs have significantly improved cancer survival at the expense
of cardiovascular toxicities, including heart disease, thromboembolic disease, and …

Cancer therapies can lead to a broad spectrum of cardiovascular complications. Among
these, cardiotoxicities remain of prime concern, but vascular toxicities have emerged as the …

Endothelial cells are at the interface between circulating blood and tissues. This position
confers on them a crucial role in controlling oxygen and nutrient exchange and cellular …

The vascular endothelial growth factor (VEGF), a homodimeric vasoactive glycoprotein, is
the key mediator of angiogenesis. Angiogenesis, the formation of new blood vessels, is …

Patients with cancer have an increased risk of both arterial and venous thrombotic events
compared with the general population. Both the site and stage of cancer are known to …